This Article Full Text Full Text (PDF) All Versions of this Article: 115/14/1876    most recent CIRCULATIONAHA.106.648790v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanner, M.A. Articles by Pennell, D.J. Search for Related Content PubMed PubMed Citation Articles by Tanner, M.A. Articles by Pennell, D.J. Related Collections Clinical genetics Other heart failure Other Treatment CT and MRI Endothelium/vascular type/nitric oxide Related Article

(Circulation. 2007;115:1876-1884.)
© 2007 American Heart Association, Inc.

Imaging

A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance

M.A. Tanner, MRCP; R. Galanello, MD; C. Dessi, MD; G.C. Smith, MSc; M.A. Westwood, MD; A. Agus, MD; M. Roughton, MSc; R. Assomull, MRCP; S.V. Nair, MRCP; J.M. Walker, MD; D.J. Pennell, MD

From the Cardiovascular Magnetic Resonance Unit (M.A.T., G.C.S., M.A.W., R.A., D.J.P.) and Health Services Research Unit (M.R.), Royal Brompton Hospital, London, UK; Ospedale Regionale per le Microcitemie, Cagliari, Italy (R.G., C.D., A.A.); and Department of Cardiology, University College Hospital, London, UK (S.V.N., J.M.W.).

Correspondence to Dr Dudley Pennell, Professor of Cardiology, Royal Brompton Hospital, Sydney St, London SW3 6NP, UK. E-mail d.pennell{at}ic.ac.uk

Received August 1, 2006; accepted January 24, 2007.

Background— Cardiac complications secondary to iron overload are the leading cause of death in ß-thalassemia major. Approximately two thirds of patients maintained on the parenteral iron chelator deferoxamine have myocardial iron loading. The oral iron chelator deferiprone has been demonstrated to remove myocardial iron, and it has been proposed that in combination with deferoxamine it may have additional effect.

Methods and Results— Myocardial iron loading was assessed with the use of myocardial T2* cardiovascular magnetic resonance in 167 patients with thalassemia major receiving standard maintenance chelation monotherapy with subcutaneous deferoxamine. Of these patients, 65 with mild to moderate myocardial iron loading (T2* 8 to 20 ms) entered the trial with continuation of subcutaneous deferoxamine and were randomized to receive additional oral placebo (deferoxamine group) or oral deferiprone 75 mg/kg per day (combined group). The primary end point was the change in myocardial T2* over 12 months. Secondary end points of endothelial function (flow-mediated dilatation of the brachial artery) and cardiac function were also measured with cardiovascular magnetic resonance. There were significant improvements in the combined treatment group compared with the deferoxamine group in myocardial T2* (ratio of change in geometric means 1.50 versus 1.24; P=0.02), absolute left ventricular ejection fraction (2.6% versus 0.6%; P=0.05), and absolute endothelial function (8.8% versus 3.3%; P=0.02). There was also a significantly greater improvement in serum ferritin in the combined group (–976 versus –233 µg/L; P<0.001).

Conclusions— In comparison to the standard chelation monotherapy of deferoxamine, combination treatment with additional deferiprone reduced myocardial iron and improved the ejection fraction and endothelial function in thalassemia major patients with mild to moderate cardiac iron loading.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2007 115: 1823. [Full Text]

This article has been cited by other articles:

				E. Vichinsky Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia Pediatrics, June 1, 2008; 121(6): 1253 - 1256. [Full Text] [PDF]

				W.-Y. Au, W. W.-m. Lam, W. W.C. Chu, H.-L. Yuen, A. S.-C. Ling, R. C.-H. Li, H. M.-H. Chan, H. K.-K. Lee, M.-F. Law, H. S. Y. Liu, et al. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong Haematologica, May 1, 2008; 93(5): 784 - 786. [Full Text] [PDF]

				E. Angelucci, G. Barosi, C. Camaschella, M. D. Cappellini, M. Cazzola, R. Galanello, M. Marchetti, A. Piga, and S. Tura Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders Haematologica, May 1, 2008; 93(5): 741 - 752. [Abstract] [Full Text] [PDF]

				W. Li, T. Coates, and J. C. Wood Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major Haematologica, February 1, 2008; 93(2): 311 - 312. [Abstract] [Full Text] [PDF]

				R. G Assomull, D. J Pennell, and S. K Prasad Cardiovascular magnetic resonance in the evaluation of heart failure Heart, August 1, 2007; 93(8): 985 - 992. [Full Text] [PDF]